Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 Initial trials 2 References

Amycretin

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.^[1]^[2]^[3]^[4]^[5]

Initial trials

[edit]

On 7 March 2024, Novo Nordisk announced the results from the Phase I trial of the pill form of Amycretin showed participants lost 13.1% of their weight after 12 weeks. For comparison, clinical trials for the older drug Wegovy which was also developed by Novo Nordisk indicated weight loss of 6% after 12 weeks and 15% after 68 weeks.^[6]

Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecasts the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.^[6]

References

[edit]

^ Melson, Eka; Ashraf, Uzma; Papamargaritis, Dimitris; Davies, Melanie J. (1 February 2024). "What is the pipeline for future medications for obesity?". International Journal of Obesity: 1–19. doi:10.1038/s41366-024-01473-y. ISSN 1476-5497.

^ Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug". MarketWatch. Retrieved 11 March 2024.

^ Jamaluddin, Aqfan; Gorvin, Caroline M (21 March 2023). "RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis". Journal of Molecular Endocrinology. 70 (4). Bioscientifica. doi:10.1530/jme-23-0014. ISSN 0952-5041. PMC 10160555.

^ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663. ISSN 1467-7881.

^ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (March 2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663.

^ ^a ^b ""Novo valuation surpasses Tesla on experimental obesity drug data"". Reuters. 7 March 2024. Retrieved 13 March 2024.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Amycretin&oldid=1217242601" Categories: ●GLP-1 receptor agonists ●Amylin receptor agonists Hidden categories: ●Articles with short description ●Short description is different from Wikidata ●Orphaned articles from March 2024 ●All orphaned articles ●Use dmy dates from March 2024 ●This page was last edited on 4 April 2024, at 17:35 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view